Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Raiola, Anna Maria  [Clear All Filters]
Journal Article
Sbragia E, Boffa G, Varaldo R, Raiola AMaria, Ghiso A, Gambella M, Benedetti L, Angelucci E, Inglese M. An aggressive form of MOGAD treated with aHSCT: A case report. Mult Scler. 2023:13524585231213792.
Sorà F, Di Grazia C, Chiusolo P, Raiola AMaria, Bregante S, Mordini N, Olivieri A, Iori APaola, Patriarca F, Grisariu S, et al. Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2019.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):106.
Metafuni E, Cavattoni IMaria, Lamparelli T, Raiola AMaria, Ghiso A, Galaverna F, Gualandi F, Di Grazia C, Dominietto A, Varaldo R, et al. Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation. Blood Adv. 2021.
Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A, Raiola AMaria, Metafuni E, Di Grazia C, Gualandi F, et al. Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen. Am J Hematol. 2020.
Gambella M, Bregante S, Raiola AMaria, Varaldo R, Ghiso A, Schiavetti I, Carmisciano L, Bacigalupo A, Angelucci E. Haploidentical hemopoietic cell transplantation for myelofibrosis, in ruxolitinib era. Transplant Cell Ther. 2022.
Nagler A, Labopin M, Tischer J, Raiola AMaria, Kunadt D, Vydra J, Blaise D, Chiusolo P, Fanin R, Winkler J, et al. Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT. Blood Adv. 2024.
Furfaro E, Nicolini L, Vecchia ADella, Di Grazia C, Raiola AMaria, Varaldo R, Ferrando F, Barisione G, Bruzzone B, Angelucci E, et al. HEV infection in an Italian cohort of HSCT recipients: seroprevalence and infection. Biol Blood Marrow Transplant. 2020.
Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Mariotti J, Raiola AMaria, Evangelista A, Harbi S, Patriarca F, Carella MAngelo, Martino M, Risitano A, Busca A, Giaccone L, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):58.
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
Velázquez GFilippini, Labopin M, Tischer J, Raiola AMaria, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C-E, Kröger N, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.